COX Inhibitor Pack
COX Inhibitor Pack
The Cayman COX Inhibitor Pack contains a combination of frequently used cyclooxygenase (COX) inhibitors. Each kit contains aspirin, the archetype...
€932.00
ViewPrice:
From €507.00 €430.95
From €507.00 €430.95
BAM-22P (8-22) is an endogenous neuropeptide derived from proenkephalin A and an agonist of MAS-related G protein-coupled receptor family member X1 (MRGPRX1), previously known as sensory neuron-specific G protein-coupled receptor 4 (SNSR4).{67100} It is involved in prurition and nociception. BAM-22P (8-22) induces calcium mobilization in HEK293S cells expressing human MRGPRX1 or SNSR3 (EC50s = 14 and 28 nM, respectively) and inhibits voltage-induced calcium currents in isolated rat neurons expressing human MRGPRX1 (EC50 = 0.6 µM).{67101} Intrathecal administration of BAM-22P (8-22) (30 nmol/animal) decreases the tail-flick latency in rats stimulated with the G?i inhibitor pertussin toxin and increases the tail-flick latency in rats stimulated with the phospholipase C (PLC) inhibitor U-73122, indicating changes in pain sensitivity.{67102} BAM-22P (8-22) (100 µg/animal) increases scratching behavior in wild-type mice and enhances bile-duct ligation-induced scratching behavior in a mouse model of cholestasis.{67103}
Territorial Availability: Available through Bertin Technologies only in France
| Size | 1 mg, 10 mg, 5 mg |
|---|---|
| Shipping | dry ice |
| Molecular formula | C91H127N25O23S • XCF3COOH |
| Smiles | OC(CNC([C@H](CC1=CC=C(O)C=C1)NC([C@H](CCCNC(N)=N)NC([C@H](CCCCN)NC([C@H](CCC(N)=O)NC([C@H](CC2=CC=C(O)C=C2)NC([C@H](CC(O)=O)NC([C@H](CCSC)NC([C@H](CC3=CNC4=CC=CC=C34)NC([C@@H](NC([C@H](CCC(O)=O)NC([C@H]5N(CCC5)C([C@H](CCCNC(N)=N)NC(CNC([C@@H](N)C(C)C)=O)=O)=O)=O)=O)CC6=CNC7=CC=CC=C67)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O |
| Molecular weight | 1971,2 |
| Custom code | 2933.99 |
| Formulation | A solid |
| Purity | ≥95% |
| UNSPSC code | 12352100 |
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.
The Cayman COX Inhibitor Pack contains a combination of frequently used cyclooxygenase (COX) inhibitors. Each kit contains aspirin, the archetype...
To be used in conjunction with Cayman’s FABP3 polyclonal antibody (Catalog No. 10233) to block protein-antibody complex formation during immunochemical...
To be used in conjunction with Cayman’s NAPE-PLD polyclonal antibody (aa 6-20) (Item No. 10306) to block protein-antibody complex formation...
Headquarters:
Parc d’activités du Pas du Lac
10 bis avenue Ampère
78180 Montigny le Bretonneux
France
Copyright © 2024 BERTIN BIOREAGENT. All rights reserved | Terms & conditions
